In KRAS G12C-mutant advanced NSCLC patients with first-line metastatic disease, regardless of PD-L1 expression, combining LY3537982 with pembrolizumab demonstrated promising antitumor activity and favorable safety, with infrequent low-grade TRAEs [67]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.